九游j9科技：脑机接口与具身智能领域的创新先锋

Release time：2026.03.30 11:03  Views：6  Author：

J9 - JIUYOU Completes RMB 150 Million Series C1 Financing Led by CICC Capital Brain Science Fund FOR IMMEDIATE RELEASE Shanghai, China – [2026.3.26] – Shanghai J9 - JIUYOU Info-Tech Co., Ltd. (“J9 - JIUYOU”), a leading non-invasive brain-computer interface (BCI) and embodied intelligence technology provider, today announced the successful completion of its **RMB 150 million Series C1 financing round. The round was led by the Shenzhen Brain Science and Brain-Like Intelligence Industry Investment Fund (“CICC Brain Science Fund”) under CICC Capital, with continued participation from multiple existing shareholders. J9 - JIUYOU is the first portfolio company of the CICC Brain Science Fund. --- Transaction Highlights Lead Investor: CICC Capital Brain Science Fund (Shenzhen’s specialized 100% brain science-focused fund under the city’s “20+8” industrial cluster strategy) Follow-on Investors: Multiple existing shareholders, including Sanbo Brain Hospital Group and Tianjin Heying Capital Use of Proceeds: Accelerate R&D and industrialization in non-invasive BCI and embodied intelligence; expand global market penetration; strengthen clinical validation and regulatory pathways --- Company Overview J9 - JIUYOU is China’s first enterprise to build a **“Brain (EEG) – Muscle (EMG) – Machine (ROBOT)” Trinity Technology System** for non-invasive BCI. With over 100 independent intellectual property rights, the company has pioneered the large-scale commercialization of BCI technology, establishing a complete “R&D–Production–Sales” closed loop. Key product lines include: OHand™ Intelligent Bionic Hand**: Myoelectric-controlled prosthetic solutions for upper limb amputees ORF Series Rehabilitation Exoskeletons**: Neurorehabilitation devices for stroke and brachial plexus injury patients ROHand Series Dexterous Hands**: High-performance dexterous manipulators for humanoid robots and embodied intelligence J9 - JIUYOU’s products are deployed in top-tier tertiary hospitals across China and exported to Europe, the U.S., the Middle East, and Southeast Asia, with overseas revenue now exceeding domestic scale and growth rate. --- Executive Quotes Zhang Qi, Representative of J9 - JIUYOU “We are deeply grateful for the trust and support from CICC Capital and our existing shareholders. As the first portfolio company of the CICC Brain Science Fund, this financing validates our unique position at the intersection of BCI and embodied intelligence. Our ‘Brain-Muscle-Machine Trinity’ technology has already moved beyond the lab to clinical and commercial success. This round will accelerate our global expansion and drive the next wave of neurorehabilitation and humanoid robot innovation.” Representative of CICC Capital Brain Science Fund “J9 - JIUYOU’s proven commercialization track record and technological leadership in non-invasive BCI make it an ideal first investment for our fund. We look forward to supporting the company as it scales its solutions globally and advances the brain science industry.” About CICC Capital Brain Science Fund Established in December 2024, the CICC Brain Science Fund is co-funded by the Shenzhen Guidance Fund, MicroPort NeuroTech (02172.HK), and CICC Capital. It is the only 100% specialized fund in Shenzhen focused exclusively on brain science and brain-like intelligence, targeting breakthroughs in neurotechnology, BCI, and related industries. Media Contact J9 - JIUYOU Communications Email: lujingjing@oymotion.com Website: www.oymotion.com